Biomarkers for the lung cancer diagnosis and their advances in proteomics

142Citations
Citations of this article
132Readers
Mendeley users who have this article in their library.

Abstract

Over a last decade, intense interest has been focused on bio-marker discovery and their clinical uses. This interest is accelerated by the completion of human genome project and the progress of techniques in proteomics. Especially, cancer bio-marker discovery is eminent in this field due to its anticipated critical role in early diagnosis, therapy guidance, and prognosis monitoring of cancers. Among cancers, lung cancer, one of the top three major cancers, is the one showing the highest mortality because of failure in early diagnosis. Numerous potential DNA biomarkers such as hypermethylations of the promoters and mutations in K-ras, p53, and protein biomarkers; carci-noembryonic antigen (CEA), CYFRA21-1, plasma kallikrein B1 (KLKB1), Neuron-specific enolase, etc. have been discovered as lung cancer biomarkers. Oespite extensive studies thus far, few are turned out to be useful in clinic. Even those used in clinic do not show enough sensitivity, specificity and reproducibility for general use. This review describes what the cancer biomarkers are for, various types of lung cancer biomarkers dis-covered at present and predicted future advance in lung cancer biomarker discovery with proteomics technology.

Cite

CITATION STYLE

APA

Sung, H. J., & Cho, J. Y. (2008). Biomarkers for the lung cancer diagnosis and their advances in proteomics. Journal of Biochemistry and Molecular Biology. The Biochemical Society of the Republic of Korea. https://doi.org/10.5483/bmbrep.2008.41.9.615

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free